PARP1 and cancer: Taken together with our earlier findings that a combination of Wi-A and CAPE caused selective cytotoxicity in cancer cells through the modulation of p53-mortalin and PARP1 signaling [36], we report that a low dose combination of Wi-A and CAPE (Wi-ACAPE) possesses significant anti-metastasis and anti-angiogenic potentials, warranting further experimental and clinical trials.